Bonne Biesma

9.5k citations

95 papers · 6.5k indexed · 2 hit papers · h-index 34

Impact in

Oncology top 0.5%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Neutropenia and Cancer Infections
Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment

Papers in

Oncology 66
- Lung Cancer Research Studies 50
- Neutropenia and Cancer Infections 19
- Colorectal Cancer Treatments and Studies 8
Pulmonary and Respiratory Medicine 59
- Lung Cancer Treatments and Mutations 52
- Lung Cancer Diagnosis and Treatment 29
- Occupational and environmental lung diseases 6

Co-authors: Egbert F. Smit Joachim von Pawel Johan Vansteenkiste Giorgio V. Scagliotti Christian Manegold Filippo de Marinis Keunchil Park Lorinda Simms
Journals: Journal of Clinical Oncology (29 papers)Lung Cancer (12 papers)Annals of Oncology (9 papers)British Journal of Cancer (6 papers)Journal of Thoracic Oncology (6 papers)
Partner nations: Netherlands Belgium Germany

In The Last Decade

Bonne Biesma

92 papers receiving 6.3k citations

Hit Papers

align trajectories log scale

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer 2008 · 2.5k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2008 Journal of Clinical Oncology
2007 JNCI Journal of the National Cancer Institute

Peers

Countries citing papers authored by Bonne Biesma

Since Specialization

Citations

This map shows the geographic impact of Bonne Biesma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bonne Biesma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bonne Biesma more than expected).

Fields of papers citing papers by Bonne Biesma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bonne Biesma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bonne Biesma. The network helps show where Bonne Biesma may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Bonne Biesma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bonne Biesma Line = papers co-authored together Bonne Biesma links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial Cancer Chemotherapy and Pharmacology ·J W Rose, René J. Boosman, Jacobus A. Burgers, Alwin D. R. Huitema, Anne‐Marie C. Dingemans, Hieronymus J. Derijks, David M. Burger, Berber Piet, Lizza Hendriks, Bonne Biesma, Filip Ccaron ulo, Daphne W. Dumoulin, Sander Croes, Ron H.J. Mathijssen, Michel M. van den Heuvel, Rob ter Heine	2022	0
2	International real-world study of DLL3 expression in patients with small cell lung cancer Lung Cancer ·Federico Rojo, Marcelo Corassa, Dimitriοs Mavroudis, Büğe Öz, Bonne Biesma, Luka Brčić, Patrick Pauwels, Verena Sailer, John R. Gosney, Darko Miljkovic, Carlos Hader, Meijing Wu, José Raymundo Torres-Fabela, Frédérique Penault‐Llorca	2020	42
3	Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial Frontiers in Oncology ·Pengfei Qiu, Lizza Hendriks, Vincent van der Noort, 山梨県立考古博物館, Franz M.N.H. Schramel, Harry J.M. Groen, Bonne Biesma, Hans J.M. Smit, Anne‐Marie C. Dingemans	2020	4
4	A randomized phase II study comparing paclitaxel–carboplatin–bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170) Annals of Oncology ·Anne‐Marie C. Dingemans, Harry J.M. Groen, Gerarda J.M. Herder, Jos A. Stigt, Egbert F. Smit, Idris Bahce, J.A. Burgers, Ben E.E.M. van den Borne, Bonne Biesma, Andrew Vincent, Vincent van der Noort, Qun Li	2015	30
5	Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer Lung Cancer ·Gerald Schmid‐Bindert, Vittorio Gebbia, Frank Mayer, Edurne Arriola, Diego Márquez-Medina, Kostas Syrigos, Bonne Biesma, Monika I. Leschinger, Bente Frimodt‐Moller, Veronique Ripoche, Scott P. Myrand, Tuan S. Nguyen, Rebecca R. Hozak, Annamaria H. Zimmermann, Carla Visseren‐Grul, Wolfgang Schuette	2013	8
6	Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin–gemcitabine or carboplatin–paclitaxel: NVALT-3 a phase III study Annals of Oncology ·Bonne Biesma, A.N.M. Wymenga, Andrew Vincent, Otilia Dalesio, Hans J.M. Smit, Jos A. Stigt, Egbert F. Smit, Intan Pratiwi, J.W.G. van Putten, Joris P. J. Slaets, Harry J.M. Groen	2011	79
7	Pneumonectomy for bronchogenic carcinoma: analysis of factors predicting short- and long-term outcome Interactive Cardiovascular and Thoracic Surgery ·Eelco J. Veen, M.L.G. Janssen‐Heijnen, Ewan Ritchie, Bonne Biesma, Vicky Hurtado Valenzuela, L.V. Samokhina	2009	9
8	Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, U. Gatzemeier, Raghunadharao Digumarti, Mauro Zukin, Florian Doetzer, Anders Mellemgaard, Keunchil Park, Bonhyeok Gu, Janusz Rolski, Tuncay Göksel, Filippo de Marinis, Lorinda Simms, Katherine P. Sugarman, David R. Gandara Hit paper breakdown →	2008	2487
9	P2-239: A randomized phase III study of carboplatin-gemcitabine (CG) versus carboplatin-paclitaxel (CP) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) with emphasis on geriatric assessment and quality of life (QoL): The NVALT-3 study Journal of Thoracic Oncology ·Bonne Biesma, James Wm. White, Andrew Vincent, Otilia Dalesio, Jos A. Stigt, Hans J.M. Smit, Harry J.M. Groen	2007	5
10	C6-01: Correlations of biomarker expression and clinical outcome in a large phase III trial of pemetrexed plus cisplatin or gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) Journal of Thoracic Oncology ·Giorgio V. Scagliotti, Christopher Kaiser, Bonne Biesma, Christian Manegold, U. Gatzemeier, Piotr Serwatowski, خنوس محمد الهادي, Beatrix Bálint, Hans J.M. Smit, Johan Vansteenkiste	2007	9
11	A3-05: Phase III study of vinflunine versus docetaxel in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with a platinum containing regimen Journal of Thoracic Oncology ·Rodryg Ramlau, Jaafar Bennouna, Eng Huat Tan, Bonne Biesma, Armando Santoro, C. Boni, Helmut Klein, Larasati Rizki Saswin, Ricard Mesı́a, 竜一郎濱本	2007	0
12	Negligible influence of comorbidity on prognosis of patients with small cell lung cancer: A population-based study in the Netherlands Critical Reviews in Oncology/Hematology ·M.L.G. Janssen‐Heijnen, V.E.P.P. Lemmens, Ben E.E.M. van den Borne, Bonne Biesma, S.B. Oei, J.W.W. Coebergh	2007	34
13	Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer JNCI Journal of the National Cancer Institute ·Jan P. van Meerbeeck, G. Kramer, Paul Van Schil, Cathérine Legrand, Egbert F. Smit, Franz M.N.H. Schramel, Vivianne C. G. Tjan‐Heijnen, Bonne Biesma, C. Debruyne, Nico van Zandwijk, Ted A.W. Splinter, Giuseppe Giaccone Hit paper breakdown →	2007	471
14	Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975 Annals of Oncology ·Fabio Efficace, Andrew Bottomley, Egbert F. Smit, P. Lianes, Catherine Legrand, C. Debruyne, Franz M.N.H. Schramel, Henk Smit, Rabab Gaafar, Bonne Biesma, C. Manegold, Corneel Coens, Giuseppe Giaccone, Jan P. van Meerbeeck	2006	150
15	Non-small cell lung cancer and health-related quality of life (HRQOL): Is baseline HRQOL of prognostic value for survival? Open Repository and Bibliography (University of Liège) ·Andrew Bottomley, Egbert F. Smit, Fabio Efficace, W. TELFER, Hans J.M. Smit, Rabab Gaafar, Bonne Biesma, P. Lianes, Kristel Van Steen, Corneel Coens, Jan P. van Meerbeeck	2005	1
16	Recombinant human interleukin‐3 administered concomitantly with chemotherapy in patients with relapsed small cell lung cancer PubMed ·Bonne Biesma, Klaas W. van Kralingen, Edwin Dias, C Nakcha, Pieter E. Postmus	2002	1
17	Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study Annals of Oncology ·Vivianne C. G. Tjan‐Heijnen, Pieter E. Postmus, Andrea Ardizzoni, C. Manegold, J Burghouts, Jan P. van Meerbeeck, Steven Gans, Camila R. S. Bartsch, 正明神山, Bonne Biesma, Catherine Legrand, C. Debruyne, Giuseppe Giaccone	2001	79
18	A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy Lung Cancer ·Bonne Biesma, Egbert F. Smit, Pieter E. Postmus	1999	11
19	Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study. Journal of Clinical Oncology ·Pieter E. Postmus, Jourik A. Gietema, Hye Kyu Kim, Bonne Biesma, P. C. Limburg, Edo Vellenga, Elisabeth G.E. de Vries	1992	65
20	Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers British Journal of Cancer ·Bonne Biesma, Phb Willemse, NH Mulder, 慶江荒川, MI Yuanzh, Thomas Bartnik, PE Postmus, 森島陽介, Elisabeth G.E. de Vries	1992	41

About Bonne Biesma

Bonne Biesma is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Geriatrics and Gerontology, Otorhinolaryngology and Hepatology, having authored 95 papers that have together received 6.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (52 papers), Lung Cancer Research Studies (50 papers), Lung Cancer Diagnosis and Treatment (29 papers), Neutropenia and Cancer Infections (19 papers), Cancer therapeutics and mechanisms (12 papers), Neuroendocrine Tumor Research Advances (11 papers), Colorectal Cancer Treatments and Studies (8 papers) and Occupational and environmental lung diseases (6 papers). The work is most often cited by research in Oncology (4.3k citations), Pulmonary and Respiratory Medicine (4.4k citations), Cancer Research (686 citations), Otorhinolaryngology (152 citations) and Hematology (254 citations). Bonne Biesma has collaborated with scholars based in Netherlands, Belgium and Germany. Frequent co-authors include Egbert F. Smit, Joachim von Pawel, Johan Vansteenkiste, Giorgio V. Scagliotti, Christian Manegold, Filippo de Marinis, Keunchil Park, Lorinda Simms, Katherine P. Sugarman and David R. Gandara. Their work appears in journals such as Journal of Clinical Oncology, Lung Cancer, Annals of Oncology, British Journal of Cancer and Journal of Thoracic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact